Unum Therapeutics Inc (NASDAQ:UMRX) – Stock analysts at Wedbush issued their Q1 2020 earnings per share (EPS) estimates for Unum Therapeutics in a research note issued to investors on Tuesday, November 5th. Wedbush analyst D. Nierengarten anticipates that the company will post earnings per share of ($0.20) for the quarter. Wedbush currently has a “Outperform” rating and a $13.00 target price on the stock. Wedbush also issued estimates for Unum Therapeutics’ Q2 2020 earnings at ($0.21) EPS, Q3 2020 earnings at ($0.23) EPS, Q4 2020 earnings at ($0.20) EPS, FY2022 earnings at ($1.44) EPS and FY2023 earnings at ($0.96) EPS.
A number of other brokerages also recently issued reports on UMRX. ValuEngine upgraded Unum Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. HC Wainwright restated a “buy” rating on shares of Unum Therapeutics in a research note on Tuesday, August 13th. Cowen restated a “hold” rating on shares of Unum Therapeutics in a research note on Monday, August 12th. Finally, Zacks Investment Research upgraded Unum Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research note on Saturday. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Unum Therapeutics presently has a consensus rating of “Buy” and an average price target of $9.63.
Unum Therapeutics (NASDAQ:UMRX) last announced its earnings results on Monday, August 12th. The company reported ($0.34) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.05. The firm had revenue of $3.14 million during the quarter, compared to analysts’ expectations of $3.10 million. Unum Therapeutics had a negative return on equity of 75.60% and a negative net margin of 340.49%.
A number of hedge funds have recently made changes to their positions in the stock. Acadian Asset Management LLC grew its stake in Unum Therapeutics by 134.8% during the 2nd quarter. Acadian Asset Management LLC now owns 32,601 shares of the company’s stock worth $85,000 after buying an additional 18,717 shares during the last quarter. Tower Research Capital LLC TRC purchased a new position in Unum Therapeutics during the 3rd quarter worth $31,000. Susquehanna International Group LLP purchased a new position in Unum Therapeutics during the 2nd quarter worth $62,000. Wedbush Securities Inc. purchased a new position in Unum Therapeutics during the 3rd quarter worth $48,000. Finally, Jane Street Group LLC purchased a new position in Unum Therapeutics during the 2nd quarter worth $132,000. Hedge funds and other institutional investors own 42.07% of the company’s stock.
Unum Therapeutics Company Profile
Unum Therapeutics Inc, a clinical stage biopharmaceutical company, develops and commercializes immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The company's lead product candidate is the ACTR707 used in combination with rituximab, which is in Phase I clinical trials to treat adult patients with relapsed or refractory CD20+ B cell non-Hodgkin lymphoma (r/r NHL).
Recommended Story: Options Trading – What is a Straddle?
Receive News & Ratings for Unum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.